Neveda

Nevada Therapeutics is a pre-clinical stage biotechnology company focused on developing novel cancer immunotherapies. The company's primary focus is on targeting the Sialyl-Tn (STn) antigen, a carbohydrate structure that is overexpressed on the surface of many solid tumor cells but has limited expression in normal tissues. By developing high-affinity monoclonal antibodies against STn and its biosynthetic enzyme ST6GALNAC1, Nevada Therapeutics aims to create targeted therapies that can selectively eliminate cancer cells while minimizing off-target effects. Their research is rooted in discoveries made at the University of Nevada, Reno, and they are currently advancing their lead candidates through early-stage development.